Clinical Outcomes of Neoadjuvant Chemotherapy in Colorectal Cancer Patients With Synchronous Resectable Liver Metastasis: A Propensity Score Matching Analysis

Annals of Coloproctology

Yoon Ah Park¹  Yong Beom Cho¹  Jin Seok Heo¹  Woo Yong Lee¹  Gyu Seong Choi¹  Jung Kyong Shin¹  Sung Hae Park¹  Jung Wook Huh¹  Seong Hyeon Yun¹  Hee Cheol Kim¹  Seung Tae Kim²  Young Suk Park² 

[1] Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea;Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea;

关键词: colorectal neoplasms;    liver metastases;    neoadjuvant therapy;   

DOI  :  10.3393/ac.2020.00710.0101

来源: DOAJ

【 摘 要 】

Purpose The survival benefit of neoadjuvant chemotherapy (NAC) prior to surgical resection in colorectal cancer with liver metastases (CRCLM) patients remains controversial. The aim of this study was to compare overall outcome of CRCLM patients who underwent NAC followed by surgical resection versus surgical treatment first. Methods We retrospectively analyzed 429 patients with stage IV colorectal cancer with synchronous liver metastases who underwent simultaneous liver resection between January 2008 and December 2016. Using propensity score matching, overall outcome between 60 patients who underwent NAC before surgical treatment and 60 patients who underwent surgical treatment first was compared. Results Before propensity score matching, metastatic cancer tended to involve a larger number of liver segments and the primary tumor size was bigger in the NAC group than in the primary resection group, so that a larger percentage of patients in the NAC group underwent major hepatectomy (P < 0.001). After propensity score matching, demographic features and pathologic outcomes showed no significant differences between the 2 groups. In addition, there was no significant difference in short-term recovery outcomes such as postoperative morbidity (P = 0.603) and oncologic outcome, including 3-year overall survival rate (P = 0.285) and disease-free survival rate (P = 0.730), between the 2 groups. Conclusion NAC prior to surgical treatment in CRCLM is considered a safe treatment that does not increase postoperative morbidity, and its impact on oncologic outcome was not inferior.

【 授权许可】

Unknown